STVN:NYE-Stevanato Group SpA (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 18.88

Change

+0.08 (+0.43)%

Market Cap

USD 4.94B

Volume

0.25M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-0.90 (-0.38%)

USD 68.65B
ALC Alcon AG

-1.24 (-1.31%)

USD 46.87B
RMD ResMed Inc

-1.38 (-0.56%)

USD 37.59B
BAX Baxter International Inc

-0.13 (-0.36%)

USD 18.36B
AVTR Avantor Inc

-0.06 (-0.27%)

USD 15.33B
ATR AptarGroup Inc

+0.33 (+0.20%)

USD 11.25B
TFX Teleflex Incorporated

-1.22 (-0.52%)

USD 11.21B
BLCO Bausch + Lomb Corp

-0.32 (-1.54%)

USD 7.32B
WRBY Warby Parker Inc

+0.20 (+1.18%)

USD 2.09B
INFU InfuSystems Holdings Inc

-0.19 (-3.01%)

USD 0.15B

ETFs Containing STVN

CIC:CA CI Canadian Banks Covered.. 16.77 % 0.84 %

+0.02 (+0.00%)

N/A
BANK:CA Evolve Canadian Banks and.. 12.23 % 0.39 %

-0.02 (0.00%)

CAD 0.26B
BNC:CA Purpose Canadian Financia.. 12.02 % 0.68 %

-0.01 (0.00%)

N/A
HCB:CA 6.95 % 0.65 %

N/A

N/A
BFIN-U:CA 5.72 % 0.00 %

N/A

N/A
INOC:CA Global X Inovestor Canadi.. 4.42 % 0.66 %

N/A

CAD 0.04B
FBE:CA 2.65 % 0.83 %

N/A

N/A
DXIF:CA Dynamic Active Internatio.. 0.00 % 0.00 %

N/A

CAD 3.68M

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.82% 42% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.82% 42% F 22% F
Trailing 12 Months  
Capital Gain -26.68% 42% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.68% 42% F 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.13% 74% C 75% C
Dividend Return 14.13% 74% C 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.67% 53% F 23% F
Risk Adjusted Return 33.12% 79% B- 50% F
Market Capitalization 4.94B 43% F 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.